Among previously uninfected young girls in China, the 9-valent HPV vaccine does not appear to be cost effective compared with bivalent or quadrivalent vaccines, and is only marginally cost effective when up against no vaccination according to an economic modelling analysis published in BMJ Open....
The HPV, or human papillomavirus, vaccine is recommended for adolescents at age 11 or 12, although it can be given starting at age 9 and up to age 45. It protects men and women against HPV strains that can cause six types of cancer. The Healthy People 2030 goal is to have 80 percent...
从 2017 年 1 月开始，HPV 9 价疫苗也成功入列，所有拥有学校、公司以及个人私人保险计划的小伙伴，只要前往 in-network 医疗机构，都将不需要花费任何 cost-sharing，免费接种 HPV 三针疫苗。常见的私人保险公司 Aetna，Blue Cross Blue Shield，UnitedHealthcare 等将覆盖 HPV 疫苗接种的花销。如果没有私人保险的...
4价的紧缺(供需比)势必会缓解，而9价的“充足”也会迅速消失今儿下午刚听负责疫苗业务的同事聊天，说...
[3] Estimated Human Papillomavirus Vaccine Coverage Among Females 9–45 Years of Age — China, 2017–2022 (chinacdc.cn) [4] https://app.powerbi.com/view?r=eyJrIjoiNDIxZTFkZGUtMDQ1Ny00MDZkLThiZDktYWFlYTdkOGU2NDcwIiwidCI6ImY2M...
[9] Verdoodt F, Dehlendorff C, Kjaer SK. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study. Clin Infect Dis. 2020;70(4):60...
赶紧拿起手机,订购吧!不对,预约GP吧! 参考网站: [1]http://www.hpvvaccine.org.au/the-hpv-vaccine/how-effective-is-the-vaccine.aspx http://www.hpvvaccine.org.au/the-hpv-vaccine/cost.aspx 作者:四月 公众号:晚安四月 id:bonnenuitavril 授权转载/...
为什么9到15岁是最佳接种年龄呢?因为这个年龄段是在性启蒙之前。疫苗的作用是预防感染,可以让人在接触到这个病毒之前有一个保护。与此同时,年轻人的免疫系统也比较年轻、比较活跃,对疫苗的反应也更好。 另外我也比较痛心的是,我经常遇到一些妈妈,她和我说打了HPV疫苗,“我去了香港,还托了关系,花了好几千才打...
单剂量HPV疫苗评估联盟(Single-Dose HPV Vaccine Evaluation Consortium),该联盟由PATH协调成立,包括哈佛大学、伦敦卫生与热带医学学院、拉瓦尔大学、英属哥伦比亚大学、美国疾病控制和预防中心、美国国家癌症研究所、Wits生殖健康和HIV研究所以及Kirby新南威尔士大学研究所。
Objectives In France, 9-valent HPV vaccination is recommended routinely for 11–14-years-old girls and as catch-up for 15–19-years-old girls. Recently, re... LM A,XB B,NEM C,... - 《Vaccine》 被引量: 0发表: 2021年 High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness...